Association of changes in norepinephrine and serotonin transporter expression with the long-term behavioral effects of antidepressant drugs

Neuropsychopharmacology

Volumn 34, Issue 6, 2009, Pages 1467-1481

  Zhao, Zaorui ^a,c   Zhang, Han Ting ^a   Bootzin, Elianna ^a   Millan, Mark J ^b   O'Donnell, James M ^a  

^a WEST VIRGINIA UNIVERSITY   (United States)

^b YALE UNIVERSITY   (United States)

^c INSTITUT DE RECHERCHES INTERNATIONALES SERVIER   (France)

Author keywords

Antidepressant drugs; Norepinephrine transporter; P chlorophenylalanine; Serotonin transporter

Indexed keywords

ANTIDEPRESSANT AGENT; FENCLONINE; MESSENGER RNA; NORADRENALIN TRANSPORTER; PHENELZINE; PROTRIPTYLINE; REBOXETINE; SEROTONIN TRANSPORTER; SERTRALINE; VENLAFAXINE;

ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BEHAVIOR CHANGE; BRAIN CORTEX; CONTROLLED STUDY; DORSAL RAPHE NUCLEUS; DOWN REGULATION; DRUG EFFECT; FORCED SWIMMING TEST; HIPPOCAMPUS; LOCUS CERULEUS; MALE; MINIPUMP; NEUROTRANSMISSION; NONHUMAN; NORADRENERGIC SYSTEM; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; SEROTONINERGIC SYSTEM; TREATMENT DURATION;

ANIMALS; ANTIDEPRESSIVE AGENTS, SECOND-GENERATION; ANTIDEPRESSIVE AGENTS, TRICYCLIC; BRAIN; CYCLOHEXANOLS; DEPRESSION; DOWN-REGULATION; FENCLONINE; MALE; MONOAMINE OXIDASE INHIBITORS; MORPHOLINES; NOREPINEPHRINE PLASMA MEMBRANE TRANSPORT PROTEINS; PHENELZINE; PROTEIN SYNTHESIS INHIBITORS; PROTRIPTYLINE; RATS; RATS, SPRAGUE-DAWLEY; RNA, MESSENGER; SEROTONIN ANTAGONISTS; SEROTONIN PLASMA MEMBRANE TRANSPORT PROTEINS; SEROTONIN UPTAKE INHIBITORS; SERTRALINE;

EID: 64949105244     PISSN: 0893133X     EISSN: None     Source Type: Journal    
DOI: 10.1038/npp.2008.183     Document Type: Article

References (91)

1. Abumaria N, Rygula R, Hiemke C, Fuchs E, Havemann-Reinecke U, Rüther E et al (2007). Effect of chronic citalopram on serotonin-related and stress-regulated genes in the dorsal raphe nucleus of the rat. Eur Neuropsychopharmacol 17: 417-429.
2. Amano T, Aoki S, Setsuie R, Sakurai M, Wada K, Noda M (2006). Identification of a novel regulatory mechanism for norepinephr-ine transporter activity by the IP3 receptor. Eur J Pharmacol 536: 62-68.
3. Artigas F, Celada P, Laruelle M, Adell A (2001). How does pindolol improve antidepressant action? Trends Pharmacol Sci 22: 224-228.
4. Benmansour S, Altamirano AV, Jones DJ, Sanchez TA, Gould GG, Pardon MC et al (2004). Regulation of the norepinephrine transporter by chronic administration of antidepressants. Biol Psychiatry 55: 313-316.
5. Benmansour S, Cecchi M, Morilak DA, Gerhardt GA, Javors MA, Gould GG et al (1999). Effects of chronic antidepressant treatments on serotonin transporter function, density, and mRNA level. J Neurosci 19: 10494-10501.
6. Benmansour S, Owens WA, Cecchi M, Morilak DA, Frazer A (2002). Serotonin clearance in vivo is altered to a greater extent by antidepressant- induced downregulation of the serotonin transporter than by acute blockade of this transporter. J Neurosci 22: 6766-6772.
7. Beyer CE, Boikess S, Luo B, Dawson LA (2002). Comparison of the effects of antidepressants on norepinephrine and serotonin concentrations in the rat frontal cortex: an in-vivo microdialysis study. J Psychopharmacol 16: 297-304.
8. Bremner JD, Vythilingam M, Ng CK, Vermetten E, Nazeer A, Oren DA et al (2003). Regional brain metabolic correlates of alpha-methylparatyrosine- induced depressive symptoms: implications for the neural circuitry of depression. JAMA 289: 3125-3134.
9. Bryan-Lluka LJ, Paczkowski FA, Bonisch H (2001). Effects of short-and long-term exposure to c-AMP and c-GMP on the noradrena-line transporter. Neuropharmacology 40: 607-617.
10. Cadieux RJ (1999). Antidepressant drug interactions in the elderly. Understanding the P-450 system is half the battle in reducing risks. Postgrad Med 106: 231-249.
11. Chamas F, Serova L, Sabban EL (1999). Tryptophan hydroxylase mRNA levels are elevated by repeated immobilization stress in rat raphe nuclei but not in pineal gland. Neurosci Lett 267: 157-160.
12. Chamas FM, Underwood MD, Arango V, Serova L, Kassir SA, Mann JJ et al (2004). Immobilization stress elevates tryptophan hydroxylase mRNA and protein in the rat raphe nuclei. Biol Psychiatry 55: 278-283.
13. Charney DS (1998). Monoamine dysfunction and the pathophy-siology and treatment of depression. J Clin Psychiatry 59: 11-14.
14. Charney DS, Price LH, Heninger GR (1986). Desipramine-yohimbine combination treatment for refractory depression. Arch Gen Psychiatry 45: 1155-1161.
15. 2 agonist augments gamma-aminobutyric acid and excitatory amino acid inputs to noradrenergic locus coeruleus neurons. Neuroscience 54: 409-420.
16. Crissman AM, O'Donnell JM (2002). Effects of antidepressants in rats trained to discriminate centrally administered isoproterenol. J Pharmacol Exp Ther 302: 606-611.
17. Cryan JF, Markou A, Lucki L (2002). Assessing antidepressant activity in rodents: recent developments and future needs. Trends Pharmacol Sci 23: 238-245.
18. Cryan JF, O'Leary OF, Jin SH, Friedland JC, Ouyang M, Hirsch BR et al (2004). Norepinephrine-deficient mice lack responses to antidepressant drugs, including selective serotonin reuptake inhibitors. Proc Natl Acad Sci 101: 8186-8191.
19. 3H]imipramine. J Pharmacol Exp Ther 242: 364-371.
20. Deupree JD, Montgomery MD, Bylund DB (2007). Pharmacological properties of the active metabolites of the antidepressants desipramine and citalopram. Eur J Pharmacol[3H]576: 55-60.
21. Dickinson SL (1990). Alpha2-adrenoceptor antagonism and depression. Drug News Perspect 4: 197-203.
22. Dunah AW, Standaert DG (2001). Dopamine D1 receptor-dependent trafficking of striatal NMDA glutamate receptors to the postysynaptic membrane. J Neurosci 21: 5546-5558.
23. Frazer A (2001). Serotonergic and noradrenergic reuptake inhibitors: prediction of clinical effects from in vitro potencies. J Clin Psychiatry 62: 16-23.
24. Frazer A, Benmansour S (2002). Delayed pharmacological effects of antidepressants. Mol Psychiatry 7: S23-S28.
25. Gelenberg AJ, Chesen CL (2000). How fast are antidepressants? J Clin Psychiatry 61: 712-721.
26. Gould GG, Altamirano AV, Javors MA, Frazer A (2006). A comparison of the chronic treatment effects of venlafaxine and other antidepressants on serotonin and norepinephrine transporters. Biol Psychiatry 59: 408-414.
27. Gould GG, Pardon MC, Morilak DA, Frazer A (2003). Regulatory effects of reboxetine treatment alone, or following paroxetine treatment, on brain noradrenergic and serotonergic systems. Neuropsychopharmacology 28: 1633-1641.
28. 1A receptor function in brain following agonist or antidepressant administration. Life Sci 72: 1665-1682.
29. Hirano K, Kimura R, Sugimoto Y, Yamada J, Uchida S, Kato Y et al (2005a). Relationship between brain serotonin transporter binding, plasma concentration and behavioural effect of selective serotonin reuptake inhibitors. Br J Pharmacol 144: 695-702.
30. Hirano K, Seki T, Sakai N, Kato Y, Hashimoto H, Uchida S et al (2005b). Effects of continuous administration of paroxetine on ligand binding site and expression of serotonin transporter protein in mouse brain. Brain Res 1053: 154-161.
31. Horschitz S, Hummerich R, Schloss P (2001). Down-regulation of the rat serotonin transporter upon exposure to a selective serotonin reuptake inhibitor. Neuroreport 12: 2181-2184.
32. Iceta R, Mesonero JE, Alcalde AI (2007). Effect of long-term fluoxetine treatment on the human serotonin transporter in Caco-2 cells. Life Sci 80: 1517-1524.
33. Iversen L (2006). Neurotransmitter transporters and their impact on the development of psychopharmacology. Br J Pharmacol 147: S82-S88.
34. Jayanthi LD, Samuvel DJ, Ramamoorthy S (2004). Regulated internalization and phosphorylation of the native norepinephrine transporter in response to phorbol esters. Evidence for localization in lipid rafts and lipid raft-mediated internalization. J Biol Chem 279: 19315-19326.
35. Katz MM, Koslow SH, Frazer A (1996). Onset of antidepressant activity: reexamining the structure of depression and multiple actions of drugs. Depress Anxiety 4: 257-267.
36. Katz MM, Tekell JL, Bowden CL, Brannan S, Houston JP, Berman N et al (2004). Onset and early behavioral effects of pharmacologically different antidepressants and placebo in depression. Neuropsychopharmacology 29: 566-579.
37. Koe BK, Weissman A (1966). p-Chlorophenylalanine: a specific depletory of brain serotonin. J Pharmacol Exp Ther 154: 499-516.
38. Kozisek ME, Deupree JD, Burke WJ, Bylund DB (2007). Appropriate dosing regimens for treating juvenile rats with desipramine for neuropharmacological and behavioral studies. J Neurosci Methods 163: 83-91.
39. Kugaya A, Seneca NM, Snyder PJ (2003). Changes in human in vivo serotonin and dopamine transporter availabilities during chronic antidepressant administration. Neuropsychopharmacology 28: 413-420.
40. Lam RW, Tam EM, Grewal A, Yatham LN (2001). Effects of alpha-methyl-para-tyrosine-induced catecholamine depletion in patients with seasonal affective disorder in summer remission. Neuropsychopharmacology 25: S97-S101.
41. Lapiz MD, Zhao Z, Bondi CO, O'Donnell JM, Morilak DA (2007). Blockade of autoreceptor-mediated inhibition of norepinephrine release by atipamezole is maintained after chronic reuptake inhibition. Int J Neuropsychopharmacol 10: 827-833.
42. Larsen MB, Elfving B, Wiborg O (2004). The chicken serotonin transporter discriminates between serotonin-selective reuptake inhibitors. A species-scanning mutagenesis study. J Biol Chem 279: 42147-42156.
43. Lau T, Horschitz S, Berger S, Bartsch D, Schloss P (2008). Antidepressant-induced internalization of the serotonin transporter in serotonergic neurons. FASEB J 22: 1702-1714.
44. Laux G, Volz HP, Moller HJ (1995). Newer and older monoamine oxidase inhibitors: a comparative profile. CNS Drugs 3: 145-148.
45. Lenox RA, Frazer A (2002). Mechanism of action of antidepres-sants and mood stabilizers. In: Davis KL, et al, (eds). Neuropsychopharmacology: The Fifth Generation of Progress. American College of Neuropsychopharmacology: Nashville, TN. pp 1139-1163.
46. Lesch PK, Aulakh CS, Wolozin BL, Tolliver TJ, Hill JL, Murphy DL (1993). Regional brain expression of serotonin transporter mRNA and its regulation by reuptake inhibiting antidepressants. Mol Brain Res 17: 31-35.
47. Lin JW, Wyszynski M, Madhavan R, Sealock R, Kim JU, Sheng M (1998). Yotiao, a novel protein of neuromuscular junction and brain that interacts with specific splice variants of NMDA receptor subunit NR1. J Neurosci 18: 2017-2027.
48. Lopez JF, Chalmers DT, Vazquez DM, Watson SJ, Akil H (1994). Serotonin transporter mRNA in rat brain is regulated by classical antidepressants. Biol Psychiatry 35: 287-290.
49. López-MuñToz F, Alamo C, Juckel G, Assion HJ (2007). Half a century of antidepressant drugs: on the clinical introduction of monoamine oxidase inhibitors, tricyclics, and tetracyclics. Part I: monoamine oxidase inhibitors. J Clin Psychopharmacol 27: 555-559.
50. Millan MJ (2006). Multi-target strategies for the improved treatment of depressive states: conceptual foundations and neuronal substrates, drug discovery and therapeutic application. Pharmacol Ther 110: 135-370.
51. Millan MJ, Gobert A, Lejeune F, Newman-Tancredi A, Rivet JM, Auclair A (2001). S33005, a novel ligand at both serotonin and norepinephrine transporters: II. Behavioral profile in comparison with venlafaxine, reboxetine, citalopram, and clomipra-mine. J Pharmacol Exp Ther 298: 565-580.
52. Millan MJ, Gobert A, Rivet JM, Adhumeau-Auclair A, Cussac D, Newman-Tancredi A et al (2000). Mirtazapine enhances frontocortical dopaminergic and corticolimbic adrenergic, but not serotonergic, transmission by blockade of alpha2-adrenergic and serotonin2C receptors: a comparison with citalopram. Eur J Neurosci 12: 1079-1095.
53. Miller HL, Delgado PL, Salomon RM, Berman R, Krystal JH, Heninger GR et al (1996a). Clinical and biochemical effects of catecholamine depletion on antidepressant-induced remission of depression. Arch Gen Psychiatry 53: 117-128.
54. Miller HL, Delgado PL, Salomon RM, Heninger GR, Charnery DS (1996b). Effects of alpha-methyl-para-tyrosine (AMPT) in drug-free depressed patients. Neuropsychopharmacology 14: 151-157.
55. 2-adrenoceptors on 5-hydroxytryptamine terminals in the rat hippocampus. Naunyn Schmiedebergs Arch Pharmacol 347: 266-272.
56. Morilak DA, Frazer A (2004). Antidepressants and brain mono-aminergic systems: a dimensional approach to understanding their behavioral effects in depression and anxiety disorders. Int J Neuropsychopharmacol 7: 193-218.
57. Nelson JC, Mazure CM, Jatlow PI, Bowers Jr MB, Price LH (2004). Combining norepinephrine and serotonin reuptake inhibition mechanisms for treatment of depression: a double-blind, randomized study. Biol Psychiatry 56: 535-546.
58. O'Donnell JM, Marek GJ, Seiden LS (2005). Antidepressant effects assessed using behavior maintained under a differential-reinforcement-of-low-rate (DRL) operant schedule. Neurosci Biobehav Rev 29: 785-798.
59. O'Donnell JM, Seiden LS (1984). Altered effects of desipramine on operant performance after 6-hydroxydopamine-induced depletion of brain dopamine or norepinephrine. J Pharmacol Exp Ther 229: 629-635.
60. O'Leary OF, Bechtholt AJ, Crowley JJ, Hill TE, Page ME, Lucki I (2007). Depletion of serotonin and catecholamines block the acute behavioral response to different classes of antidepressant drugs in the mouse tail suspension test. Psychopharmacology 192: 357-371.
61. Ordway GA, Gambarana C, Tejani-Butt SM, Areso P, Hauptmann M, Frazer A (1991). Preferential reduction of binding of 125I-iodopindolol to beta-1 adrenoceptors in the amygdala of rat after antidepressant treatments. J Pharmacol Exp Ther 257: 681-690.
62. Owens MJ, Morgan WN, Plott SJ, Nemeroff CB (1997). Neuro-transmitter receptor and transporter binding profile of antidepressants and their metabolites. J Pharmacol Exp Ther 283: 1305-1322.
63. Page ME, Detke MJ, Dalvi A, Kirby LG, Luckii I (1999). Serotonergic mediation of the effects of fluoxetine, but not desipramine, in the rat forced swimming test. Psychopharmacology 147: 162-167.
64. Page ME, Lucki I (2002). Effects of acute and chronic reboxetine treatment on stress-induced monoamine efflux in the rat frontal cortex. Neuropsychopharmacology 27: 237-247.
65. Paxinos G, Watson C (1998). The Rat Brain in Stereotaxic Coordinates, 4th edn. Academic Press: San Diego.
66. Porsolt RD, Le PM, Jalfre M (1977). Depression: a new animal model sensitive to antidepressant treatments. Nature 266: 730-732.
67. Qian Y, Galli A, Ramamoorthy S, Risso S, DeFelice LJ, Blakely RD (1997). Protein kinase C activation regulates human serotonin transporters in HEK-293 cells via altered cell surface expression. J Neurosci 17: 45-57.
68. Rossi DV, Valdez M, Gould GG, Hensler JG (2005). Chronic administration of venlafaxine fails to attenuate 5-HT1A receptor function at the level of receptor-G protein interaction. Int J Neuropsychopharmacol 8: 1-14.
69. Salomon RM, Miller HL, Delgado PL, Charney D (1993). The use of tryptophan depletion to evaluate central serotonin function in depression and other neuropsychiatric disorders. Int Clin Psychopharmacol (Suppl) 2: 41-46.
70. Scates AC, Doraiswamy PM (2000). A selective norepinephrine reuptake inhibitor for the treatment of depression. Ann Pharmacother 34: 1302-1312.
71. Schmid JA, Just H, Sitte HH (2001). Impact of oligomerization on the function of the human serotonin transporter. Biochem Soc Trans 29: 732-736.
72. Smith PK, Krohn PI, Hermanson GT, Mallia AK, Gartner FH, Provenzano MD et al (1985). Measurement of protein using bicinchoninic acid. Anal Biochem 150: 76-85.
73. Sung U, Blakely RD (2007). Calcium-dependent interactions of the human norepinephrine transporter with syntaxin 1A. Mol Cell Neurosci 34: 251-260.
74. Sung U, Jennings JL, Link AJ, Blakely RD (2005). Proteomic analysis of human norepinephrine transporter complexes reveals associations with protein phosphatase 2A anchoring subunit and 14-3-3 proteins. Biochem Biophys Res Commun 333: 671-678.
75. Szot P, Ashliegh EA, Kohen R, Petrie E, Dorsa DM, Veith R (1993). Norepinephrine transporter mRNA is elevated in the locus ceruleus following short- and long-term desipramine treatment. Brain Res 618: 308-312.
76. Tanaka E (1998). Clinically important pharmacokinetic drug-drug interactions: role of cytochrome P450 enzymes. J Clin Pharm Ther 23: 403-416.
77. 3H-nisoxetine: a new radioligand for norepinephrine uptake sites in brain. Eur J Pharmacol 191: 239-243.
78. Thakker DR, Natt F, Hüsken D, van der Putten H, Maier R, Hoyer D et al (2005). siRNA-mediated knockdown of the serotonin transporter in the adult mouse brain. Mol Psychiatry 10: 782-789.
79. Thase ME, Trivedi MH, Rush AJ (1995). MAOIs in the contemporary treatment of depression. Neuropsychopharmacology 12: 185-219.
80. Versiani M, Mehilane L, Gaszner P, Arnaud-Castiglioni R (1999). Reboxetine, a unique selective NRI, prevents relapse and recurrence in long-term treatment of major depressive disorder. J Clin Psychiatry 60: 400-406.
81. Weinshenker D, White SS, Javors MA, Palmiter RD, Szot P (2002). Regulation of norepinephrine transporter abundance by cate-cholamines and desipramine in vivo. Brain Res 946: 239-246.
82. White KJ, Walline CC, Barker EL (2005). Serotonin transporters: implications for antidepressant drug development. AAPS J 7: E421-E433.
83. Wong EH, Sonders MS, Amara SG, Tinholt PM, Piercey MF, Hoffmann WP et al (2000). Reboxetine: a pharmacologically potent, selective, and specific norepinephrine reuptake inhibitor. Biol Psychiatry 47: 818-829.
84. Wyszynski M, Kharazia V, Shanghvi R, Rao A, Beggs AH, Craig AM et al (1998). Differential regional expression and ultrastructural localization of alpha-actinin-2, a putative NMDA receptor anchoring protein, in rat brain. J Neurosci 18: 1383-1392.
85. Xie T, Tong L, McLane MW, Hatzidimitriou G, Yuan J, McCann U et al (2006). Loss of serotonin transporter protein after MDMA and other ring-substituted amphetamines. Neuropsychopharmacology 31: 2639-2651.
86. Zhang HT, Huang Y, Masood A, Stolinski LR, Li Y, Zhang L et al (2008). Anxiogenic-like behavioral phenotype of mice deficient in phosphodiesterase 4B (PDE4B). Neuropsychopharmacology 33: 1611-1623.
87. Zhao Z, Baros AM, Zhang HT, Lapiz MD, Bondi CO, Morilak DA et al (2008). Norepinephrine transporter regulation mediates the long-term behavioral effects of the antidepressant desipramine. Neuropsychopharmacology. print copy in press (originally published online Apr. 16, 2008 at http://www.nature.com/npp/journal/vaop/ncurrent/abs/npp200845a.html).
88. Zhu MY, Blakely RD, Apparsundaram S, Ordway GA (1998). Down-regulation of the human norepinephrine transporter in intact 293-hNET cells exposed to desipramine. J Neurochem 70: 1547-1555.
89. Zhu MY, Kim CH, Hwang DY, Baldessarini RJ, Kim KS (2002). Effects of desipramine treatment on norepinephrine transporter gene expression in the cultured SK-N-BE(2)M17 cells and rat brain tissue. J Neurochem 82: 146-153.
90. Zhu MY, Ordway GA (1997). Down-regulation of norepinephrine transporters on PC12 cells by transporter inhibitors. J Neurochem 68: 134-141.
91. Zhu MY, Wang WP, Baldessarini RJ, Kim KS (2005). Effects of desipramine treatment on tyrosine hydroxylase gene expression in cultured neuroblastoma cells and rat brain tissue. Brain Res Mol Brain Res 133: 167-175.